EANM position on the in-house preparation of radiopharmaceuticals

Harry Hendrikse; Oliver Kiss; Jolanta Kunikowska; Wolfgang Wadsak; Clemens Decristoforo; Marianne Patt

doi:10.1007/s00259-022-05694-z

EANM position on the in-house preparation of radiopharmaceuticals

Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1095-1098. doi: 10.1007/s00259-022-05694-z.

Authors

Harry Hendrikse¹, Oliver Kiss², Jolanta Kunikowska³, Wolfgang Wadsak⁴, Clemens Decristoforo^#⁵, Marianne Patt^#⁶

Affiliations

¹ Department of Clinical Pharmacology & Pharmacy, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
² Department of Radiopharmaceuticals Production, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
³ Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.
⁴ Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, AKH Wien, Waehringer Guertel 18-20, A-1090, Vienna, Austria. [email protected].
⁵ Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
⁶ Department for Nuclear Medicine, University of Leipzig, Leipzig, Germany.

^# Contributed equally.

PMID: 35050391
DOI: 10.1007/s00259-022-05694-z

Abstract

The EANM herewith clearly expresses its commitment and support to the non-commercial in-house preparation of radiopharmaceuticals for direct use in accordance with European and national regulations.

Publication types

Editorial

MeSH terms

Humans
Nuclear Medicine*
Radiopharmaceuticals*

Substances

Radiopharmaceuticals